期刊
TRENDS IN MOLECULAR MEDICINE
卷 16, 期 5, 页码 203-209出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2010.02.005
关键词
-
资金
- National Institute of Health [DE019191]
- American Heart Association [0970178N]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095722] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE019191] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086433] Funding Source: NIH RePORTER
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has riot been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据